AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy – Business Wire

Posted on by

CAMBRIDGE, Mass,--(BUSINESS WIRE)--AXONIS Therapeutics, Inc., an emerging biotechnology company advancing breakthrough research to treat spinal cord injury and paralysis, today announced the close of the first tranche of a $4 million Seed Preferred financing. The financing was led by Kerry Murphy, an investor, philanthropist and AXONIS Board member. The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity. The importance of KCC2 treatment in recovery of stepping ability was first discovered by Dr. Zhigang He in his lab at Boston Childrens Hospital.

We are very pleased with this seed funding, as it will allow us to initiate important pre-clinical work and build our team as we advance this technology, said Joanna Stanicka, PhD, CEO, AXONIS Therapeutics. We have seen very promising results in the proof-of-concept studies thus far, and look forward to moving this critical research to the next stage in our mission to treat paralysis.

Many years in academia, biotechnology and pharma have given me the experience and perspective to recognize the importance of Dr. Hes discovery and what AXONIS is aiming to achieve, said Corey Goodman, PhD, Executive Chair and co-founder of AXONIS. That background underscores my excitement in AXONIS neuromodulating therapy not only for spinal cord injury, the initial focus, but also other neurological disorders, such as epilepsy, where it also has major potential.

The second tranche of the financing will be provided following the Companys successful delivery of proof-of-concept data, which is expected in approximately one year. The financing follows the strengthening of the leadership team including the appointment of Dr. Stanicka as CEO in October 2019, along with an expanded Board of Directors. Under the new leadership, AXONIS received state and federal non-dilutive funding and other seed investment. Dr. Stanicka also won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral in Cambridge.

AXONIS has licensed or optioned two technologies from Boston Childrens Hospital, the leading pediatric hospital in the world. In addition to its primary work on the KCC2 protein, AXONIS has also been investigating PTEN inhibition to help regenerate nerve connections after injury. Through tissue reactivation and nerve regeneration, AXONIS is focused on identifying effective therapies to restore movement in paralyzed patients after spinal cord injury.

Spinal cord injury causes devastating paralysis, loss of sensation and loss of other bodily functions below the level of the injury. Across the US, Canada and Western Europe, it is estimated that there are more than 3.6 million cases, and more than 180,000 new cases each year, with each SCI patient requiring more than $100,000, on average, in annual care.

AXONIS Science Advisory Council includes Oswald Steward, PhD, Director of the Reeve-Irvine Research Center at the University of California at Irvine; Lisa McKerracher, PhD, CEO, BioAxone BioSciences, Inc.; and Dr. Goodman, Managing Partner, venBio Partners.

AXONIS was founded by Bob Yant, a well-known advocate for spinal cord regeneration research. Following a 1981 accident that left Bob a quadriplegic, he has dedicated significant time to raising funds for basic research aimed at developing a cure for spinal cord injury. Bob is a former Director of the Christopher and Dana Reeve Foundation, and Founder of Cure Medical.

About AXONIS Therapeutics

AXONIS Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, committed to developing groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders. AXONIS is advancing two breakthrough discoveries, KCC2 upmodulation to reactivate spared tissue and PTEN inhibition to regenerate injured nerve connections, to make a real difference for patients, their families, and the global healthcare system. For more information, visit http://www.axonis.us

The rest is here:
AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy - Business Wire

GREEN VISION BIOTECHNOLOGY : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) – marketscreener.com

Posted on by

GENERAL

Green Vision Biotechnology Corp. (the "Company"), formerly known as VibeWireless Corp., also formerly known as Any Translation Corp., was incorporatedunder the laws of the State of Nevada on July 5, 2012. We were founded to be inthe business of translation and interpretation. The Company undertooktranslation and interpretation projects for various fields from business,economics, to science issues. The Company later adopted a business plan topursue business opportunities in the global telecommunications industry.

On September 2, 2015, a change in control of the Company took place by virtue ofthe Company's largest shareholder and sole officer and director at that time,selling 4,000,000 shares of the Company's common stock to Forestbay CapitalPartners II, LLC, a Delaware limited liability company. Such shares represented65.8% of the Company's total issued and outstanding shares of common stock. Aspart of the sale of the shares, Forestbay Capital Partners arranged with theformer officer and director, prior to his resignation as the sole officer anddirector of the Company Board, to appoint Mr. Edward Mooney as the sole officerand director of the Company. Mr. Mooney is the Manager of Forestbay CapitalPartners II, LLC.

On November 12, 2015, we changed our name to Vibe Wireless Corp in connectionwith merging with our wholly-owned subsidiary. This name change and our tickersymbol change was acknowledged by FINRA and effected in the market on November23, 2015.

The Company was originally incorporated under the laws of the State of Nevada onJuly 5, 2012 as Any Translation Corp.

On September 30, 2016, the Company filed a Certificate of Amendment with theNevada Secretary of State (the "Nevada SOS") whereby it amended its Articles ofIncorporation to increase the Company's authorized number of shares of commonstock from 75 million to 750 million and forward split all of its issued andoutstanding shares of common stock at a ratio of ten (10) shares for every one(1) share held. The Company's Board of Directors approved this amendment onSeptember 30, 2016.

On September 30, 2016, the Company filed Articles of Merger with the Nevada SOSwhereby it entered into a statutory merger with its wholly-owned subsidiary,Green Vision Biotechnology Corp. pursuant to Nevada Revised Statutes 92A.200 et.seq. The effect of such merger is that the Company is the surviving entity andchanged its name to "Green Vision Biotechnology Corp."

On September 30, 2016, the Company filed an Issuer Company-Related ActionNotification Form with FINRA requesting that the aforementioned forward splitand name change be effected in the market. The Company also requested that itsticker symbol be changed to "GVBT". This name change and our ticker symbolchange was acknowledged by FINRA and effected in the market on November 27,2016.

As disclosed in our Current Report on Form 8-K dated May 12, 2017 there was achange in our management. Effective May 3, 2017, the Company accepted theresignation of Edward P. Mooney as the sole officer of the Company and as thesole member of the Company's board of directors. Simultaneously, Mr. Ma Wai Kin,was elected as the Company's President, Secretary, Treasurer and a member of theBoard of Directors.

Our financial statements have been prepared assuming that we will continue as agoing concern and, accordingly, do not include adjustments relating to therecoverability and realization of assets and classification of liabilities thatmight be necessary should we be unable to continue our operation.

We expect we will require additional capital to meet our long-term operatingrequirements. We expect to raise additional capital through, among other things,the sale of equity or debt securities.

Result of Operations for the Three months ended March 31, 2019 and 2018

Revenue was $29,834 for the three months ended March 31, 2019 ("Q1"), decreasedby $23,083, or 43.6% from $52,917 for the three months ended March 31, 2018("Comparable Quarter"). The decrease in revenue during the Q1 as compared to theComparable Quarter was due to the restrictions on our production capacity as aresult of the enforcement on new environmental regulations over industrialproduction by coal-fired boilers by local authorities in Shanxi. In thisquarter, our company has conducted various field trials in Guangxi,Heilongjiang, and Yunnan in order to promote our products.

Cost of sales was decreased by $8,245, or 22.1% from $37,255 in the ComparableQuarter to $29,010 in Q1. The decrease was due to the decrease in productioncorresponding to the decrease in the sales revenue. In terms of percentage ofrevenue, cost of sales was 97.2% in Q1 as compared to 70.4% in the ComparableQuarter. The decrease in cost of sales with the increase in percentage torevenue, was due to the significant decrease in the production level whichworsen the mass of production effect.

Gross profit was decreased by $14,838, or 94.7% from $15,662 in the ComparableQuarter to $824 in Q1. The decrease reflected the correlation in reduction ofrevenue. In terms of percentage of revenue, the gross profit percentage wasdecreased to 2.8% for Q1 as compared to 29.6% for the Comparable Quarter. Thedecrease was primarily due to the significant drop in the sales revenue withresulted to the decrease in the production level.

Selling expenses were decreased by $3,851 or 98.8% from $3,898 for theComparable Quarter to $47 in Q1. In terms of percentage of revenue, the rateswere 0.2% in Q1 compared to 7.4% in the Comparable Quarter. The decrease isprimarily due to the decrease of testing expenses and shipping andtransportation expenses which were correlated to the decrease in sales.

General and administrative expenses were decreased by $144,405, or 59.3% from$243,371 for the Comparable Quarter to $98,966 for Q1. The decrease is primarilydue to the salary and consultation fee in Q1.

The following is a summary of general and administrative expenses for the threemonths ended March 31, 2019, and 2018.

Salary and payroll expenses 15,507 54,832 (39,325 )Professional fees

Consulting fees were decreased by $42,977, or 73.4%, from $58,585 in ComparableQuarter to $15,608 in Q1, owing to the engagement of less external consultantsto improve the Company's operating activities in the Comparable Quarter.

Our salary and payroll expenses were decreased by $39,325, or 71.7%, to $15,507in Q1, as compared to $54,832 in the Comparable Quarter. We anticipate thatsalary and payroll expenses will rise in future periods as it becomes necessaryto increase our staff in order to enhance our management quality for the listingrequirement and to increase our production activities.

Professional fees were decreased by $501, from $7,909 in Comparable Quarter to$7,408 in Q1. The decrease of professional fees was due to the engagement ofless independent professionals such as international lawyers and accountants.

Travel and entertainment expenses were decreased by $11,404, or 55.0%, from$20,735 in Comparable Quarter to $9,331 in Q1. The decrease of travel andentertainment expenses was due to the reduction of project-based travellingactivities.

Research and Development expenses were decreased to $Nil in Q1 from $786 inComparable Quarter.

Depreciation and amortization expenses were decreased by $12,750, or 23.0%, from$55,428 in Comparable Quarter to $42,678 in Q1.

Other expenses include items such as office expenses, software related costs,telephone and a variety of other miscellaneous expenses. None of these expensesalone changed significantly except transportation fee, as the difference was$36,662, or 81.3% decrease from $45,096 in Comparable Quarter to $8,434 in Q1.

We anticipate that we will incur higher general and administrative expenses as apublic company. We expect that our professional fees, cost of transfer agent,investor relations costs and other stock related costs will increase.

We also anticipate that selling, general and administrative expenses willconcurrently increase with our increased activity in the future but will notincrease in the same proportion to that of revenue.

Our loss from operations was decreased by $133,418 or 57.6%, to negative $98,189in Q1, from $231,607 in Comparable Quarter.

Non-operating income (expenses) was increased by $24,201, or 1419%, to income of$22,495 in Q1, from expenses of negative $1,706 in Comparable Quarter, of whichmainly due to the increase of other income increase $28,135 from $124 inComparable Quarter to $28,259 in Q1.

The net loss attributed to the Company was reduced by $157,619, or 67.6% tonegative $75,694 in Q1, as compared to negative $233,313 in Comparable Quarter.

Liquidity and Capital Resources

The Company's liquidity and capital is dependent on whether the Company iscapable of generating its revenues and increasing its capital for thedevelopment and expansion of its business.

Management plans to support the Company's operation and its business strategy byraising funds through public and private offerings and relying on officers anddirectors to perform essential management functions with minimal compensation.If we do not raise all of the money we need from a public offering, we will haveto find alternative sources, such as a private placement of securities, or loansfrom our officers, directors or others. The loans are likely to be unsecured,non-interest bearing and repayable at demand.

Moreover, management has actively taken steps to revise its operating andfinancial needs. Management believes that the Company's current and availablecapital resources will allow it to continue its operations throughout thisfiscal year.

At March 31, 2019, we had a working capital deficit of $9,718,626, as comparedto a working capital deficit of $9,596,914 at December 31, 2018. Of the workingcapital deficit at March 31, 2019, $9,454,171 was amount due to related partiesand shareholder. Excluding the amounts due to related parties and shareholder,we would have had a negative working capital of $264,455 at March 31, 2019. Ascomparison, the working capital deficit at December 31, 2018, $9,361,322 wasamount due to related parties and holding company. Excluding the amounts due torelated parties and holding company, we would have had a negative workingcapital of $235,592 at December 31, 2018. The amounts due to related parties andshareholder are unsecured, interest free and repayable on demand.

During the three months ended March 31, 2019, operating activities used cash of$4,550, and for the comparable three months ended March 31, 2018, operatingactivities used cash in operations of $122,676. The use of cash in operatingactivities for the three months ended March 31, 2019 was mainly derived from anet loss of $75,694 with a non-cash item of $42,678 ($36,710 plus $5,968) indepreciation and amortization and negative $66,640 in inventory provisionreversal ; moreover, there was an increase in cash of $66,640 in inventories; anincrease in cash of $38,113 in other payable and an increase in cash of $21,813in accrued expenses, which were offset by a decrease in cash of $1,883 inaccounts receivable; a decrease in cash of 2,402 in accounts payable; a decreasein cash of $25,084 in accrued payroll and a decrease in cash of $2,509 in amountdue to related parties. As comparison, the use of cash in operating activitiesfor the comparable three months ended March 31, 2018 was mainly derived from anet loss of $ $233,313 with a non-cash item of $67,498 ($61,167 plus $6,331) indepreciation and amortization; moreover, there was an increase in cash of$10,230 in inventories; an increase in cash of $13,843 in other receivables; anincrease in cash of $26,664 in other payable and an increase in cash of $55,215in amount due to related parties, which were offset by a decrease in cash of$33,882 in accounts receivable; a decrease in cash of 10,613 in tax payables;and a decrease in cash of $34,942 in accrued expenses.

During the three months ended March 31, 2019, investing activities used $Nil ofcash; and for comparable three months ended March 31, 2018, investing activitiesused $2,112 of cash.

During the three months ended March 31, 2019, financing activities provided cashof $8,730; and for comparable three months ended March 31, 2018, financingactivities provided cash of $104,692. The change of cash provided by financingactivities was derived from the changes in the amounts due to our shareholder.

As at March 31, 2019, net cash and cash equivalents balance was $13,447 ascompared to balance $9,114 as at December 31, 2018.

As of March 31, 2019, stockholder's equity was negative $6,489,388, compared toa negative equity of $6,405,098 at December 31, 2018.

The source of fund for supporting the Company's business operation was loansfrom directors and shareholders. In the event the directors and shareholders donot continue to support the Company's business operation, the Company could beshort of funds and may not be able to operate any longer. The amounts due torelated parties and director are interest-free loans. These loans are unsecuredand have no fixed repayment terms.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through acombination of our existing funds, loans from third parties, other debtfacilities, or further issuances of securities. Our working capital requirementsare expected to increase in line with the growth of our business.

Existing working capital, further advances and debt instruments, and anticipatedcash flow are expected to fund our operations over the next three months. Wehave no lines of credit or other bank financing arrangements. In connection withour business plan, management anticipates additional increases in operatingexpenses and capital expenditures relating to: (i) developmental expensesassociated with a growing business; and (ii) marketing expenses. We intend tofinance these expenses with further issuances of securities, and debt issuances.Thereafter, we expect we will need to raise additional capital and generaterevenues to meet long-term operating requirements. Additional issuances ofequity or convertible debt securities will result in dilution to theshareholdings of our current shareholders. Further, such securities might haverights, preferences or privileges senior to our common stock. Additionalfinancing may not be available upon acceptable terms, or at all. If adequatefunds are not available or are not available on acceptable terms, we may not beable to take advantage of prospective new business endeavors or opportunities,which could significantly and materially restrict our business operations. Wewill have to raise additional funds in the next twelve months in order tosustain and expand our operations. We currently do not have a specific plan ofhow we will obtain such funding; however, we anticipate that additional fundingwill be in the form of equity financing from the sale of our common stock. Wehave and will continue to seek to obtain short-term loans from our directors,although no future arrangement for additional loans has been made. We do nothave any agreements with our directors concerning these loans. We do not haveany arrangements in place for any future equity financing.

Since 2017, local government of Jinzhong City, Shanxi Province, China (whereShanxi Lutu and our production plant is located) has promulgated a new set ofenvironmental regulations restricting the use of coal-fired boilers infactories. Since coal-powered generators were used in our production plant, ourproduction activities in 2019 were restricted to a certain extent.

We cannot ensure that we can comply with the new environmental regulations intime. If that is the case, our production and our production capacity may bereduced as a result. This will affect our ability to generate income and to meetthe demand of our customers, which in turn could have a material adverse effecton our financial condition and results of operations.

Due to the enforcement on new environmental regulations over industrialproduction by coal-fired boilers by local authorities in Shanxi, the Company'sproduction was restricted to a certain extent in 2017. In order to fully complywith the new environmental regulations in place, management of the Company hadplanned to carry our rectification work and expected that the rectification workcould be completed by mid of 2018 and full-scale production might resume in thesecond half of 2018. However, due to the shortage of funding to carry out therectification work on our coal-powered generators, our production activitieswere restricted since second quarter in 2018. Our production and our productioncapacity was reduced as a result, significantly affected our ability to generateincome and to meet the demand of our customers, which in turn had a materialadverse effect on our financial condition and results of operations. Themanagement had decided to maintain our business by way of sub-contracting orassignment of the production. Furthermore, the management had further researchedfor other business opportunity to utilize the reduced capacity of the propertyand equipment, in order to make better the worsened revenue.

Off-Balance Sheet Arrangements

As of the date of this Quarterly Report, we do not have any off-balance sheetarrangements that have or are reasonably likely to have a current or futureeffect on our financial condition, changes in financial condition, revenues orexpenses, results of operations, liquidity, capital expenditures or capitalresources that are material to investors.

The independent auditors' report accompanying our December 31, 2018 auditedfinancial statements filed in Form 10-K on May 15, 2020 contained an explanatoryparagraph expressing substantial doubt about our ability to continue as a goingconcern. The financial statements have been prepared "assuming that we willcontinue as a going concern," which contemplates that we will realize our assetsand satisfy our liabilities and commitments in the ordinary course of business.

Edgar Online, source Glimpses

Excerpt from:
GREEN VISION BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - marketscreener.com

Doylestown Biotechnology center, Blumberg Institute, on the front lines of coronavirus fight – The Intelligencer

Posted on by

The fight against the coronavirus is being waged in science labs right in our backyard. Scientists with the nonprofit Baruch S. Blumberg Institute, which manages the Pennsylvania Biotechnology Center community, are conducting antibodies tests in area hospitals and working on a drug candidate that shows promise for treating COVID-19.

Inside a lab in Pennsylvania Biotechnology Center, Dr. Patrick Romano held out a tray of vials, each containing serum extracted from patients and hospital employees who have recovered from COVID-19.

We are one of the first companies in the local area to be doing antibody testing against the SARS-COVID-19. We are working with local health care professionals to provide this data to help them screen their employees, said Romano, a research and innovation specialist with FlowMetric Diagnostics and a Baruch S. Blumberg Institute professor who is looking for antibodies against the COVID-19 virus.

Romano is among dozens of scientists from seven companies in the nonprofit research center who are battling the deadly virus on many fronts. FlowMetric and Serologix are working to meet the urgent demands of hospitals seeking diagnostic tests to determine if people have been exposed to COVID-19 and if they have developed antibodies.

Romano said he hopes to soon work with area hospitals to identify patients who would be candidates for convalescent serum donations, which he said is a critical need for people who are critically ill right now. Convalescent plasma is being investigated across the globe for the treatment of COVID-19 because there is research gained from previous scientific studies suggesting it might help individuals recover.

Earlier this week, Bucks County health and government officials reached out to the Biotechnology Center to discuss expanding antibodies testing capabilities.

Thousands of tests have been done here, said Timothy Block, president of both the institute and the biotechnology center, which is home to 55 biotech companies. He added that Blumberg scientists are not just working behind the scenes.

They are actively involved in fighting the crisis right now, said Block. They are responding to wherever hospitals locally are asking for help.

Responding to immediate needs to expand capacity for testing in area hospitals has been a big priority. So has researching and developing treatments.

Inside the Pennsylvania Biotechnology Center community, managed by the nonprofit Blumberg Institute on Old Easton Road in Buckingham, scientists are conducting research with a drug candidate they developed years ago to determine if it could be an effective treatment for COVID-19.

We have been working on antiviral drugs for two decades at Blumberg, said Block, founder of the virology research center and the Hepatitis B Foundation. Our focus has been hepatitis B, liver cancer and other cancers, but some of the drugs we have discovered appear to have activity against other viruses.

The nonprofit research engine of the biotechnology center, the Blumberg Institute, said two promising approaches are being developed by Bixi Life Sciences, based at the center.

For one of those projects, Iminovirs, scientists are investigating a family of drugs, called iminosugar ER glucosidase inhibitors, which significantly reduce the replication of SARS-1 (the cause of SARS). Based on how it works, it may have activity against SARS-CoV-2.

In the lab of Dr. Yizeng Yang, scientists are synthesizing mini-antibody mimetics, intended to prevent SARS-CoV 2 from binding to and attacking target cells. These would serve as artificial antibodies.

A live virus is not being used for testing at the center, and scientists are working with partnering institutions to develop their research, Block said.

We dont have the ability to test it against the actual authentic virus here, said Block, who said the project is being tested at the University of Pennsylvania Perelman School of Medicine. We are a little ways away from knowing whether the drug will have activity against the cause of COVID-19. But we are looking into our toolkit to see what we have.

While there is no way of predicting whether a cure for COVID-19 will stem from the research, Block said hes proud of scientists dedication in finding a way to fight the pandemic.

Right in our back yard, here is this busy center where scientists are rising to the occasion doing what they can, carrying out tests for COVID-19 and where research is being done for our future.

To develop that toolkit, funding the work is essential, said Lou Kassa, executive vice president and chief operating officer for the institute and the biotech center.

To foster support, the center has created a Covid-19 Blumberg Action Fund, which would help the Blumberg Institutes efforts to repurpose existing drugs and methods for the treatment and control of COVID-19.

Read the original here:
Doylestown Biotechnology center, Blumberg Institute, on the front lines of coronavirus fight - The Intelligencer

Trends Of Nanoparticles in Biotechnology and Pharmaceuticals Market Reviewed For 2020 With Industry Outlook To 2026 – Cole of Duty

Posted on by

A detailed research study on the Nanoparticles in Biotechnology and Pharmaceuticals Market was recently published by DataIntelo. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

The latest report on the Nanoparticles in Biotechnology and Pharmaceuticals Market consists of an analysis of this industry and its segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period.

Request a Sample Report of Nanoparticles in Biotechnology and Pharmaceuticals Market at: https://dataintelo.com/request-sample/?reportId=83601

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

An Outline of the Major Key Points of the Nanoparticles in Biotechnology and Pharmaceuticals Market Report:

Ask for Discount on Nanoparticles in Biotechnology and Pharmaceuticals Market Report at: https://dataintelo.com/ask-for-discount/?reportId=83601

The Geographical Landscape of the Market Include:

Buy Your Exclusive PDF Copy Now @ https://dataintelo.com/checkout/?reportId=83601

Some of the Major Highlights of TOC Covers:Chapter 1: Executive Summary

Chapter 2: Methodology & Scope

Chapter 3: Market Insights

Chapter 4: Company Profiles

For More Information on this report, Request Inquiry At: https://dataintelo.com/enquiry-before-buying/?reportId=83601

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

More:
Trends Of Nanoparticles in Biotechnology and Pharmaceuticals Market Reviewed For 2020 With Industry Outlook To 2026 - Cole of Duty

Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted on by

Intercept Pharmaceuticals Inc (ICPT) is near the top in its industry group according to InvestorsObserver. ICPT gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Intercept Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Intercept Pharmaceuticals Inc (ICPT) stock is trading at $81.86 as of 10:41 AM on Tuesday, Apr 21, a loss of -$0.75, or -0.91% from the previous closing price of $82.61. The stock has traded between $80.53 and $83.30 so far today. Volume today is less active than usual. So far 80,863 shares have traded compared to average volume of 667,682 shares.

To see InvestorsObserver's Sentiment Score for Intercept Pharmaceuticals Inc click here.

View post:
Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field? - InvestorsObserver

Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? – The News Heater

Posted on by

Vir Biotechnology, Inc. (NASDAQ:VIR) went up by 3.56% from its latest closing price when compared to the 1-year high value of $75.00 and move down -140.77%, while VIR stocks collected +6.21% of gains with the last five trading sessions. Press Release reported on 04/15/20 that VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

VIR stocks went up by 6.21% for the week, with the monthly drop of -4.89% and a quarterly performance of 83.45%. The simple moving average for the period of the last 20 days is 0.29% for VIR stocks with the simple moving average of 44.30% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -58.47% of loss for the given period.

The stock volatility was left at 11.09%, however, within the period of a single month, the volatility rate increased by 7.37%, while the shares surge at the distance of +1.30% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +70.78% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +6.21%. In addition, Vir Biotechnology, Inc. saw 147.71% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

See original here:
Why Investors Need To Watch Vir Biotechnology, Inc. (VIR)? - The News Heater

Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations – The News Heater

Posted on by

Vir Biotechnology, Inc. (NASDAQ:VIR) went down by -9.32% from its latest closing price when compared to the 1-year high value of $75.00 and move down -157.73%, while VIR stocks collected -2.25% of loss with the last five trading sessions. Press Release reported 17 hours ago that Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218

Vir Biotechnology, Inc. (NASDAQ:VIR) of the analysts out of 0 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while as overweight, rated it as hold and as sell. The average price we get from analysts is $32.00 which is $4.23 above current price. VIR currently has a short float of 1.54% and public float of 100.45M with average trading volume of 892.69K shares.

VIR stocks went down by -2.25% for the week, with the monthly drop of -2.71% and a quarterly performance of 134.11%. The simple moving average for the period of the last 20 days is -20.90% for VIR stocks with the simple moving average of 39.08% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -61.20% of loss for the given period.

The stock volatility was left at 20.50%, however, within the period of a single month, the volatility rate increased by 15.57%, while the shares sank at the distance of -13.83% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +36.56% upper at the present time.

In the course of the last 5 trading sessions, VIR went down by -2.25%, in comparison to the 20-day moving average settled at $36.56. In addition, Vir Biotechnology, Inc. saw 131.41% in overturn over the period of a single year with a tendency to cut further gains.

The current profitability levels are settled at -2110.98 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -61.54, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

More here:
Vir Biotechnology, Inc. (VIR) Plans and Analysts Expectations - The News Heater

Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 – Yahoo Finance

Posted on by

Company to Host Conference Call onWednesday, April 15, 2020, at2:00 pm PT

SAN FRANCISCO, April 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will host a Key Opinion Leader call and present an update on its Phase 1/2 hepatitis B virus (HBV) clinical trial with small interfering ribonucleic acid (siRNA) VIR-2218 on Wednesday, April 15, 2020 at 2:00 pm PT.

The call will feature a presentation by Dr. Edward J. Gane, Professor of Medicine at the University of Auckland, New Zealand and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital. Dr. Gane, who also serves as an advisor to Vir, will provide an update on the Phase 1/2 clinical trial of VIR-2218, along with Vir management.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at http://www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Companys Investors website, in addition to following the Companys press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

About VIR-2218VIR-2218 is a subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218 and the timing of VIR-2218 data disclosures. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during clinical trials and delays or disruptions on our business or clinical trials due to the COVID-19 pandemic. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Story continues

Contact:

Vir Biotechnology, Inc.

InvestorsNeera Ravindran, MDHead of Investor Relations & Strategic Communicationsnravindran@vir.bio+1-415-506-5256

MediaLindy DevereuxScient PRlindy@scientpr.com+1-646-515-5730

Follow this link:
Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 - Yahoo Finance

Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement – Agri-Pulse

Posted on by

The COVID-19 outbreak is gripping our planet like no other health crisis in recent history. Overt collaboration and policy action are required to meet this challenge and, as importantly, prepare for the future. Elevating and prioritizing the interconnectedness of living things through One Health strategies and modernizing Americas animal biotechnology regulatory approach are two policies Congress and the White House must confront. In fact, they are long overdue.

Sixty percent of human diseases begin in animals.Scientists are confident that the COVID outbreak originated in batsand then was spread through another animal and then to humans, like the 2002-03 SARS outbreak. As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

Aside from the dreadful health implications, the resulting economic costs of a pandemic are profound.The World Bank estimates that, between 1997 and 2009, the global costs from six zoonotic outbreaks exceeded $80 billion. While we wont know the total impact for some time, COVID-19 has already producedone of the sharpest economic downturns in U.S. history and is costing the U.S. treasury alone trillions of dollars.

Society was woefully unprepared for this pandemic. We must employ modern approaches to be ready for future outbreaks. One Health collaboration eliminates barriers that often exist between human health, animal health, and environmental health strategies to create smarter, multi-faceted and coordinated efforts.

BIO supports legislation such as the Advancing Emergency Preparedness Through One Health Act of 2019. This bill would direct the U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA) to coordinate with other agencies and state and local leaders to advance a national One Health framework to better prevent, prepare for, and respond to zoonotic disease outbreaks like COVID-19. Congress and the White House must factor One Health into their efforts to address future pandemics.

Animal health and wellness is a critical component of One Health strategy. To help the U.S. better prepare for the future, we need changes to the U.S. animal biotechnologyregulatory system.The U.S. governments current approach to regulating animal biotechnology as a new animal drug has all but destroyed investment and blocked market access for a host of beneficial products.

Biotechnology, for example, could armpigs with resistanceto African Swine Fever. Similarly,scientists have developed achickenthat is resistant to contracting and transmitting avian influenza.

Other innovations in animal biotechnology may be able prevent, prepare for, and respond to outbreaks of infectious diseases such as coronavirus, Ebola, MERS, Zika, among others, by providing prevention strategies andtreatments for humans.

Unfortunately, the United States regulatory system for animal biotechnology is not appropriately science- or risk-based, and as a result we are falling behind other countries, such as Brazil, where innovative start-ups are finding more support.

Indeed, despite decades of animal biotechnology research and advances, only one biotech food animal has been approved to date the AquaBounty salmon which languished in the U.S. regulatory system for more than two decades and still has not hit the market because ofpolitical interference.

The current crisis underscores the urgent need to break down roadblocks to progress.

BIO is calling on the White House to direct the U.S. Food and Drug Administration (FDA) and the USDA to clarify within 30 days a plan to overhaul the current regulatory approval process for animal biotechnology.

In alettersent to the President, BIO implores the need for a new approach that 1) more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment; 2) incentivizes research and investment in the technology; and 3) ensures safe and affordable products reach consumers as soon as possible.

A joint agreement between both agencies will help farmers, innovators, and consumers realize the benefits that modern technology can bring to the United States and the world. And just may well prevent the next potential animal to human disease outbreak.

Dana OBrien,Executive Vice President,Food & AgricultureBiotechnology Innovation Organization (BIO)

See the article here:
Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement - Agri-Pulse

Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218Company to Host Conference…

Posted on by

SAN FRANCISCO, April 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will host a Key Opinion Leader call and present an update on its Phase 1/2 hepatitis B virus (HBV) clinical trial with small interfering ribonucleic acid (siRNA) VIR-2218 on Wednesday, April 15, 2020 at 2:00 pm PT.

The call will feature a presentation by Dr. Edward J. Gane, Professor of Medicine at the University of Auckland, New Zealand and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital. Dr. Gane, who also serves as an advisor to Vir, will provide an update on the Phase 1/2 clinical trial of VIR-2218, along with Vir management.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at http://www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Companys Investors website, in addition to following the Companys press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

About VIR-2218VIR-2218 is a subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus, and tuberculosis. For more information, please visit http://www.vir.bio.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218 and the timing of VIR-2218 data disclosures. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during clinical trials and delays or disruptions on our business or clinical trials due to the COVID-19 pandemic. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Vir Biotechnology, Inc.

InvestorsNeera Ravindran, MDHead of Investor Relations & Strategic Communicationsnravindran@vir.bio+1-415-506-5256

MediaLindy DevereuxScient PRlindy@scientpr.com+1-646-515-5730

Original post:
Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218Company to Host Conference...

Cellect Biotechnology Reports Fourth Quarter and Full Year 2019 Results – BioSpace

Posted on by

TEL AVIV, Israel, April 3, 2020 /PRNewswire/ -- Cellect BiotechnologyLtd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced operating and financial results for the fourth quarter and full year ended December 31, 2019.

"We achieved a number of strategic priorities in 2019, including the IND approval to commence our first-ever trial in the U.S.," commented Dr. Shai Yarkoni, Chief Executive Officer."We plan to begin enrolling patients for this trial and completing the trial in Israel when the COVID-19 pandemic is mitigated. While these near-term events are value-enhancers, I believe that our recently announced prospective partnership with Canndoc could be a game-changer for Cellect and change our growth trajectory. It has the potential to significantly enhance our short and long term business prospects and shareholder value. As a player in the fast-growing pain management market, we would anticipate significant revenue opportunities already this year."

Recent Strategic Development

As previously announced, on March 4, 2020, the Company entered into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer and a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR),to acquire from Canndoc all rights to the use and sell Canndoc products for the reduction of opioid usage, including accumulated data, as well as on-going and pipeline of clinical trials. This commercial arrangement is subject to negotiation and approval by each company's board of directors and definitive agreements.

Additionally, the two companies signed a non-binding LOI for a full merger. Under preliminary details, Cellect will acquire from Intercure all of Canndoc outstanding shares, in exchange for additional Cellect ADRs to be in total ~95% (~93% on a fully diluted basis) of the merged company. The proposed merger is subject to independent valuation of both companies, fairness opinion by a third party, negotiation of a definitive agreement, approval of the agreement by the Company's Board of Directors and shareholders, internal approvals by Canndoc and Intercure, and customary closing conditions, including the approval of the IMCA (Israeli Medical Cannabis Agency). Upon the closing of the merger, Cellect and Canndoc will aim to fulfill all of the requirements to ensure the Company's ADRs and warrants continue trading on the Nasdaq Stock Market (Nasdaq) and, for this purpose, Intercure would commit to invest a cash sum of at least $3.0 million in any public offering that is undertaken by the Company, at a price of not less than $4.50 per ADR.

Based on the progress to date, the Company continues to expect the commercial and merger transactions will close in the second quarter of 2020.

Additional Operating Highlights:

Clinical Progress Update:

Due to the ongoing COVID-19 pandemic, the Company is experiencing clinical disruption such as:

The Company continues to take all the necessary precautions advised by global health officials to ensure the health and safety of its employees and partners. The Company is unaware of any impact on employees from pandemic related exposure or illness and is continuing to perform in-house research, including in the opioid/pain management area.

Fourth Quarter and Full Year 2019 Financial Results:

Balance Sheet Highlights:

For the convenience of the reader, the amounts have been translated from NIS into U.S. dollars, at the representative rate of exchange on December 31, 2019 (U.S. $1 = NIS 3.456).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (NASDAQ: APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's intent regarding the future potential of Cellect's technology. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Twelvemonths

ended

Twelve months ended

Three months ended

December 31,

December 31,

December 31,

2019

2019

2018

2019

2018

Unaudited

Audited

Audited

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and pershare data)

Research and development expenses

3,508

12,122

13,513

2,571

4,040

General and administrative expenses

2,954

10,210

15,734

2,378

4,733

Operating loss

6,462

22,332

29,247

4,949

8,773

Financial expenses (income) due towarrants exercisable into ADS

(2,032)

(7,022)

(7,719)

998

(4,784)

Other financial expenses (income), net

433

1,498

(1,415)

129

(238)

Total comprehensive loss

4,863

16,808

20,113

6,076

3,751

Loss per share:

Basic and diluted loss per share

0.023

0.079

0.155

0.027

0.029

Weighted average number of sharesoutstanding used to compute basic anddiluted loss per share

212,642,505

212,6432,505

129,426,091

224,087,799

130,274,953

Cellect Biotechnology Ltd

Consolidated Balance Sheet Data

ASSETS

Convenience

translation

See the article here:
Cellect Biotechnology Reports Fourth Quarter and Full Year 2019 Results - BioSpace

Industry Breakdown: Where Does Oncolytics Biotech, Inc. (ONCY) Stock Fall in the Biotechnology Field? – InvestorsObserver

Posted on by

Oncolytics Biotech, Inc. (ONCY) is around the top of the Biotechnology industry according to InvestorsObserver. ONCY received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. Oncolytics Biotech, Inc. also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 11 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 85 means the stock is more attractive than 85 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Oncolytics Biotech, Inc. (ONCY) stock is down -2.44% while the S&P 500 has risen 5.92% as of 2:02 PM on Monday, Apr 6. ONCY is down -$0.04 from the previous closing price of $1.45 on volume of 194,581 shares. Over the past year the S&P 500 is down -8.97% while ONCY is down -24.19%. ONCY lost -$1.05 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

Continue reading here:
Industry Breakdown: Where Does Oncolytics Biotech, Inc. (ONCY) Stock Fall in the Biotechnology Field? - InvestorsObserver

We aim to disrupt the biotechnology landscape with out out-of-the-box and innovative product line – Express Healthcare

Posted on by

While promoting hygiene through its products made up of waterless technology, Clensta International has created the first line of defence via shielding human beings from infection of viruses and bacteria, informs Dr Puneet Gupta, Founder and CEO, Clensta International, to Viveka RoyChowdhury

What is the impact of waterless technolgy on sanitation in the public health and sanitation sphere, against the backdrop of the coronavirus infection, which has been declared as a pandemic by the World Health Organization (WHO)?

To minimise the chances of infection and disease and thereby save many lives, we have developed the next generation tech-powered products which directly impact the common population. Besides promoting hygiene, they are also useful in inculcating a behavioural change towards the protection of the environment. This is in line with the Sustainable Development Goal (SDG 6) to ensure availability and sustainable management of water and sanitation for all.

As prevention is always better than cure, our products create the first line of defence via shielding human beings from infection of viruses and bacteria. Over the years, Clensta has been a driver of change to help and protect our loved ones by providing instant hygiene to anyone, anywhere and anytime.0 Hence, we conducted research to understand the new cleanliness regime and mindset. Interestingly, the findings reveal that 70 per cent of mothers believe cleaning is equivalent to germ-free. This waterless hand rub is an ideal offering to ensure cleanliness and underscores our commitment to maintaining a germ-free environment.

Why did you choose to focus on waterless technology for your entrepreneurial journey?

Of late, sustainability has become a new dimension for companies. There has been an emergence of startups working in the area of climate change mitigation and environmental protection. After working closely with the defence personnel, I gained an insight into their challenges. The challenge of not bathing for days, while on duty during extreme weather conditions at locations such as Siachin, Kargil or Drass motivated me towards developing waterless technology products leading to the establishment of Clensta International.

What are the important milestones in this entrepreneurial journey?

The year 2017 marked Clenstas association with IIT Delhi as our research and development centre. This was instrumental in not only providing R&D support, but it also served as a platform for new startups to implement innovative ideas. Another milestone was raising seed and pre-series A fund from Indian Angle Network and notable alumni of IIT Delhi. Clensta International has also received a grant from Biotechnology Industry Research Assistance Council (BIRAC) under BIG Scheme to scale up innovation.

We have also received an appreciation from the President of India Ram Nath Kovind, which boosted the motivation of the entire team. The overwhelming response towards the product truly indicates that people are increasingly becoming conscious of the need to protect the environment and are embracing innovation.

Are there similar products in other geographies?

Currently, there is no company working in the domain of waterless FMCG or personal hygiene space in India as extensively as we are. Hence, it can be said that ours is a one-of-a-kind concept of waterless hygiene products. Though some companies have launched waterless shampoo, we are perhaps the only organisation having waterless technology as the core idea.

What have been the sales and marketing strategies, the sales channels employed?

The marketing strategy plays an instrumental role in gaining a sustainable competitive advantage for the company. We follow a B2B sales channel wherein the product is sold via a distribution network. We deploy the right mix of channels and possess a team with in-depth expertise in healthcare marketing. Their expertise is also instilling a behavioural change towards the innovations. Of late, we have been leveraging digital marketing tools extensively, including social media platforms like Facebook and LinkedIn to connect with our target audience.

Which are the sectors that are being tapped?

Clensta International aims to promote personal hygiene while protecting the environment. The issue is largely unaddressed, especially in rural areas and urban slums. The water resources face unprecedented threat worldwide. Around 2.2 billion people do not have access to safe drinking water and 4.2 billion people lack access to adequate sanitation facilities. Hence, there is an urgent need to scale up innovation geared towards promoting efficiency in water use. If we were to talk about the healthcare sector, a patient undergoing surgery or a bed-ridden person may not bathe for days and survives in unhygienic conditions. Similarly, there is immense potential in the tourism sector as waterless products are handy for travellers. In the defence sector, soldiers deployed in extreme weather conditions such as Siachen does not have access to proper bathing facilities. Adventure enthusiasts and mountaineers too face this issue of poor hygiene. Hence, our products are relevant not only for healthcare, but also for travel and defence sectors.

How are these products being positioned to hospitals and clinics?

Clensta International is working on developing an innovative healthcare product line. Its current products waterless body bath and waterless shampoo cater to the home healthcare and hospital segments. Maintaining hygiene is of utmost importance for patients, especially those in critical situations to minimise the chances of any infection. It is here that our waterless technology comes to the rescue and provides the first line of defence against viruses and bacteria.

It is also noteworthy that alternative means of bathing such as sponging and wet towel bathing increase the chances of microbial load and transfer of bacteria and other viruses to the human body. Thus, our waterless technology comprising a simple formulation that is free of alcohol, SLS and any other harmful ingredients, is useful for maintaining basic hygiene and cleanliness. The products can be directly applied to hair and body, massaged and then can be dried off using a towel. These remove dirt, oil and grease completely. Thus, our innovative healthcare solution enables convenient, on-the-go and quick access to hygiene.

Have there been any studies done to prove that the use of such products decreases the incidence of hospital-acquired infection (HAI), also known as nosocomial infections?

Our product- Clensta Waterless Body Bath is anti-bacterial, antiseptic, and has been approved by the FDA as well as tested dermatologically. All products are being extensively used in defence, hospital and healthcare institutions. The product has also been put at trial at Madras Medical College, Multi- Super Specialty Hospital Tamil Nadu, SRM Institute of Medical Sciences and Indian Navy for antimicrobial testing.

How affordable are such products, given Indias disease burden due to infectious diseases?

Clensta International is continuously striving to make its products affordable through government support. Our products have been deemed for an essential use for the Indian Navy and will soon be a necessity for the Indian Army. We are making efforts to facilitate the availability of our products to the underprivileged section of the society through our Corporate Social Responsibility (CSR) initiative and by joining hands with various governmental institutes and hospitals. Our core idea to disseminate awareness on personal hygiene while protecting the environment is also being encouraged through our marketing strategy and social media awareness campaigns. With our CSR initiative, we are also educating children in rural areas on the significance of maintaining basic hygiene.

As a start-up, what are the policies and regulations which can spur further innovation?

It is commendable that the Indian government has undertaken various initiatives such as Start-up India, Skill India, etc to spur innovation and catalyse entrepreneurship. However, there is a scope of improvement in our existing intellectual property policy framework when it comes to addressing the issue of patent protection. Surely, in comparison to before, multiple processes have been implemented to ease the fund and grant approvals. Moreover, now, we could look forward to expediting the process of granting permissions by instituting a single-window clearance mechanism. Yet, the most daunting challenge ahead for start-ups is to minimise the go-to-market time for products and to attain a sustainable competitive advantage globally.

What are your plans for future products, overseas sales, etc.?

Our focus is to penetrate deeper into the Indian market and expand ourselves in tier II- and tier-III cities. We envision to establish ourselves as a leading player in the B2B space while exploring the possibilities of establishing ourselves in the B2C market as well. Expanding our footprints internationally is on the cards. We have already set up global operations with a subsidiary in The Netherlands and are further exploring business opportunities in Africa, Asia, the European Union, North America as well as South America. We aim to disrupt the biotechnology landscape with out of -the-box and innovative product line. We will be soon foraying into the homecare segment in an endeavour to provide sustainable solutions to Indian households while simultaneously reducing the consumption of plastic.

[emailprotected]

Excerpt from:
We aim to disrupt the biotechnology landscape with out out-of-the-box and innovative product line - Express Healthcare

There are countless reason to get interested in these stocks: :Vir Biotechnology, Inc., (NASDAQ: VIR) – News Align

Posted on by

On Monday, Shares ofVir Biotechnology, Inc., (NASDAQ: VIR), inclined/declined 36.70% and closed at $26.55 in the last trading session.

Arithmetic Moving Averages VIR:

Simple Moving Average (SMA) is easy to calculate and SMA20 one is principally looking at prime trends. The 50-day moving average is more responsive to price changes than the 200-day moving Whereas long-term trend followers generally use SMA200 and most shareholders will look for a cross up or down this average to means if the stock is in a bullish or bearish trend. SMA20 is the last stop on the bus for (ST) short-term traders. The Vir Biotechnology, Inc. having its distance from 20-days simple moving average is -0.26%, and its distance from 50-days simple moving average is 19.04%, while it has a distance of 77.29% from the 200-days simple moving average.

Working over theproductivity proportionsof business stock, the speculator will discover its ROE, ROA, ROI remaining at 0.00%, 0.00% and -41.90%, individually.

ATR remains at 8.38 while Beta component of the stock stands at 0.00. The beta component is used to check the eccentrics of the stock. The VIR stock remained 3.38% unpredictable for the week and -19.69% for the month.

Market capitalization is only an extravagant proclaim for a bright idea: it is the market estimation of an organizations remarkable offers. These Amount and numbers are found by taking the postscript cost and increasing it by the all outnumber of offers remarkable. Understanding the market top isnt merely sign if you nearly putting legitimately in stocks. It is additionally helpful for common reserve speculators, the same number of assets will list the normal or middle showcase capitalization of its property. As the name recommends, this gives the centre-ground of the stores value speculations, filling financial specialists in as to whether the reserve, for the most part, puts resources into large, mid-or little top stocks.

Vir Biotechnology, Inc.Target:

The EPS of the company is strolling at -5.76. The companys Market capitalization is $4.07BBillion.

As stocks have aP/S,P/EandP/Bestimations of 501.93, 0.00 and 1.16 separately. Its P/Cash is esteemed at 10.60.

Development in profit per offer is everything. The healthy future development in profit per share (EPS) is an amazingly significant factor in recognizing an underestimated stock. The effect of income development is exponential. As time goes on, the cost of a stock will typically go up in lockstep with its income (accepting the P/E proportion is steady). Hence stocks with higher profit development should offer the most elevated capital increases. Whats more, doubling-up the growth more than doubles the capital gain, due to the compounding effect.

Volume & Average Volume Shares:

Volume of the Vir Biotechnology, Inc. exchanged hands with 3694738 shares compared to its average daily volume of 815.24K shares. Total volume is the number of shares or deals that point towards the whole activity of a security or market for a same period.

Post Views: 175

Read more:
There are countless reason to get interested in these stocks: :Vir Biotechnology, Inc., (NASDAQ: VIR) - News Align

GE renamed Cytiva upon take-over by Danaher – European Biotechnology

Posted on by

The acquisition of GE Healthcare Life Sciences by Danaher Corporation creates a giant in contract manufacturing and development. While GE Healthcare Life Sciences, will retain its 7,000 staff and multinational operations, the company will change its name to Cytiva, combining its well-known brands and offerings KTA, Amersham, HyClone, MabSelect or Whatman with its new mother companys platform.

The mission of the newly created CDMO, which is set to generate US$3.3bn in annual revenues, is to grow in the expanding biologicals market. Emmanuel Ligner, President of Cytiva, said, "Our commitment remains to provide patients with life-changing therapies and we will continue to bring innovative technologies to market that improve our customers' productivity. The CDMO will not only help companies help outsource their biologics production but also intends to provide services to the scientific community.

According to Danaher, in 2019, more than 75% of FDA-approved biological therapies relied on Cytiva technology for manufacturing including the emerging cell and gene therapy market, a field conducting more than 1,000 regenerative medicine studies at global scale.

As the global demand for personalised medicines, and advanced biological therapies continues to grow, the company will rely on its huge capabilities in instrumentation, cell line and process development together with effective production and purification technologies. Cytiva announced it will continue to drive research collaborations, including with the Center for Advanced Biological Innovation and Manufacturing in Boston, Harvard, MIT, university hospitals and industry partners such as Fujifilm Diosynth Biotechnologies and Alexandria Real Estate Equities Inc.Cytiva's broad portfolio includes well-known brands such as KTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri.

Read the original post:
GE renamed Cytiva upon take-over by Danaher - European Biotechnology

Bayer, Novartis, and Trump convicted by Nature – European Biotechnology

Posted on by

The politically overhyped use of old malaria drugs in combination with COVID-19-specific candidates has been demonstrated to be dangerous, reports Nature Medicine.

In the prestigous paper Nature Medicine, cardiologists under Lior Jankelson report that patients with COVID-19 who were on a regimen of Novartis AGs generic malaria drug hydroxychloroquine and the antibiotic azithromycin experienced electrocardiogram abnormalities. Previous reports demonstrated that the same is true for chloroquine phosphate, an old malaria drug originally developed at Bayer AG. The authorsassessed 84 patients with COVID-19 treated at a centre in New York, USA.

Azithromycin in combination with antimalarial hydroxychloroquine has been touted by President Donald Trump as a possible "game changer" in COVID-19. Former BARDA head Rick Bright was fired because he resisted political interventions to push the use of chloroquine derivatives to treat COVID-19 despite scientific evidence of efficacy and safety according to current authorisation standards. Biocentury reported previously that Trumps preference for the cheap but antiquated malaria treatments looked more like political science than actually based on scientific evidence. Several clinical programmes coordinated by the WHO , the European Union, and the UK promote clinical testing of combinations with either chloroquine phosphate or hydroxychloroquine and may cause thousands of deaths unless they were not updated to include new findings.

Several reports demonstrated that both medications increase the risk of various types of cardiac rhythm abnormalities, such as QTc-interval prolongation and drug-inducedtorsades de pointes, and sudden cardiac death. The QTc interval is measured by an electrocardiogram and represents the time it takes for a heart to recharge between beats. A prolonged QTc interval puts a patient at risk for arrhythmia and sudden cardiac death.

Now, Jankelson and colleagues reviewed the charts and followed the QTc interval of 84 patients with COVID-19 on a 5-day oral regiment of hydroxychloroquine and azithromycin. The patients were, on average, 63 years of age and74% were male. After the patients were administered the drugs, the authors followed up with an electrocardiogram. They observed a prolonged QTc in most patients. The QTc was severely prolonged in 11% of the patients, which put them at high risk of arrhythmia and sudden cardiac death. Four patients in the cohort died from multiple organ failure a characteristic of septic shock without evidence of arrhythmia and without severe QTc prolongation.

Jankelson and colleagues found that most patients with COVID-19 who were treated with hydroxychloroquine and azithromycin experienced QTc prolongation. This may have been exacerbated by other pre-existing conditions and the severity of the SARS-CoV-2 infection. The authors conclude that the QTc in patients with COVID-19 who are treated with hydroxychloroquine and azithromycin should be monitored constantly, especially for patients with additional illnesses and those who are being treated with other QT-prolonging medications.

See the rest here:
Bayer, Novartis, and Trump convicted by Nature - European Biotechnology

Airbus and Koniku Inc. team on biotechnology solutions for aviation security operations – Intelligent Aerospace

Posted on by

TOULOUSE, France - Airbus and Koniku Inc. have made a significant step forward in the co-development of a solution for aircraft and airport security operations, by extending research activities to include biological hazard detection capabilities, as well as chemical and explosive threats.

The disruptive biotechnology solution, which was originally focused on the contactless and automated detection, tracking and location of chemicals and explosives on-board aircraft and in airports, is now being adapted, in light of the COVID-19 crisis, to include the identification of biological hazards.

Based on the power of odor detection and quantification found in nature, the technical solution, developed to meet the rigorous operational regulatory requirements of aircraft and airport security operations, uses genetically engineered odorant receptors that produce an alarm signal when they come into contact with the molecular compounds of the hazard or threat that they have been programmed to detect.

Airbus and Koniku Inc. entered into a cooperation agreement in 2017, leveraging Airbus expertise in sensor integration and knowledge of ground and on-board security operations within the aviation and defense industries as well as Konikus biotechnology know-how for automated and scalable volatile organic compound detection (via their Konikore platform).

See more here:
Airbus and Koniku Inc. team on biotechnology solutions for aviation security operations - Intelligent Aerospace

Animal Biotechnology Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

Posted on by

New Jersey, United States: Market Research Intellect has added a new research report titled, Animal Biotechnology Market Professional Survey Report 2020 to its vast collection of research reports. The Animal Biotechnology market is expected to grow positively for the next five years 2020-2026.

The Animal Biotechnology market report studies past factors that helped the market to grow as well as, the ones hampering the market potential. This report also presents facts on historical data from 2011 to 2019 and forecasts until 2026, which makes it a valuable source of information for all the individuals and industries around the world. This report gives relevant market information in readily accessible documents with clearly presented graphs and statistics. This report also includes views of various industry executives, analysts, consultants, and marketing, sales, and product managers.

Market Segment as follows:

The global Animal Biotechnology Market report highly focuses on key industry players to identify the potential growth opportunities, along with the increased marketing activities is projected to accelerate market growth throughout the forecast period. Additionally, the market is expected to grow immensely throughout the forecast period owing to some primary factors fuelling the growth of this global market. Finally, the report provides detailed profile and data information analysis of leading Animal Biotechnology company.

Animal Biotechnology Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Animal Biotechnology market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Animal Biotechnology .

The Animal Biotechnology Market research presents a study by combining primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Animal Biotechnology market growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Animal Biotechnology market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Animal Biotechnology market have also been included in the study.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208205&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Animal Biotechnology Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Animal Biotechnology Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Animal Biotechnology Market, By Deployment Model5.1 Overview

6 Animal Biotechnology Market, By Solution6.1 Overview

7 Animal Biotechnology Market, By Vertical7.1 Overview

8 Animal Biotechnology Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Animal Biotechnology Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/%ef%bb%bfanimal-biotechnology-market-size-and-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Animal Biotechnology Market Size, Animal Biotechnology Market Growth, Animal Biotechnology Market Forecast, Animal Biotechnology Market Analysis, Animal Biotechnology Market Trends, Animal Biotechnology Market

Read the original:
Animal Biotechnology Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

Nanoparticles in Biotechnology and Pharmaceuticals Market Overview by 2026: Verified Market Research Cole Reports – Cole of Duty

Posted on by

Shire

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=002

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Nanoparticles in Biotechnology and Pharmaceuticals sales at regional and national levels. This data provides a detailed and accurate analysis of volume by country and an analysis of market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia and the United States Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The chapter on the competitive landscape of the global market report contains important information on market participants such as business overview, total sales (financial data), market potential, global presence, Nanoparticles in Biotechnology and Pharmaceuticals sales and earnings, market share, prices, production locations and facilities, products offered and applied strategies. This study provides Nanoparticles in Biotechnology and Pharmaceuticals sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Why choose us:

We offer state of the art critical reports with accurate information about the future of the market.

Our reports have been evaluated by some industry experts in the market, which makes them beneficial for the company to maximize their return on investment.

We provide a full graphical representation of information, strategic recommendations and analysis tool results to provide a sophisticated landscape and highlight key market players. This detailed market assessment will help the company increase its efficiency.

The dynamics of supply and demand shown in the report offer a 360-degree view of the market.

Our report helps readers decipher the current and future constraints of the Nanoparticles in Biotechnology and Pharmaceuticals market and formulate optimal business strategies to maximize market growth.

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Nanoparticles in Biotechnology and Pharmaceuticals market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Nanoparticles in Biotechnology and Pharmaceuticals market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Nanoparticles in Biotechnology and Pharmaceuticals Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

See the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market Overview by 2026: Verified Market Research Cole Reports - Cole of Duty

Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? – InvestorsObserver

Posted on by

The 75 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 87 percent of stocks in the Biotechnology industry, CARAs 75 overall rating means the stock scores better than 75 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cara Therapeutics Inc (CARA) stock is trading at $15.81 as of 11:14 AM on Wednesday, Apr 22, a rise of $0.39, or 2.53% from the previous closing price of $15.42. The stock has traded between $15.29 and $16.44 so far today. Volume today is below average. So far 328,715 shares have traded compared to average volume of 541,813 shares.

To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.

Read the original:
Biotechnology Industry: Does Cara Therapeutics Inc (CARA) Stock Beat its Rivals? - InvestorsObserver